Transcriptomic analysis of ovarian cancer cells after drug administration and tRNA transfection at 10 and 24 hours

SLFN11 sensitizes cancer cells to DNA-damaging agents (DDAs) by cleaving and reducing tRNALeu(TAA). In this study, we investigated how the reduction of tRNALeu(TAA) contributes to cell death under Camptothecin (CPT) treatment. RNA-seq and proteome analyses were performed to assess the global effects of tRNALeu(TAA) transfection. The results suggest that tRNALeu(TAA) influences the expression of proteins essential for proteostasis, particularly those involved in ubiquitin-dependent proteolysis, at the protein level rather than the mRNA level. These findings indicate that SLFN11 plays a crucial role in proteostasis by regulating tRNAs, and thus determines cell fate under DDA treatment. RNA-seq analysis of ovarian cancer cells (TOV-112D cells) was performed at 10 and 24 hours after treatment under the following three conditions to assess transcriptomic changes: 1: Treatment with transfection reagent followed by treatment with DMSO 2: Treatment with transfection reagent followed by treatment with 100nM Camptothecin 3: Treatment with transfection reagent and 10nM tRNALeu(TAA) followed by treatment with 100nM Camptothecin